Kalaris Therapeutics, Inc. (KLRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has a cash flow conversion efficiency ratio of -0.195x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.35 Million) by net assets ($68.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KLRS equity financing ratio to measure how much of total assets are equity-financed.
Kalaris Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Kalaris Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kalaris Therapeutics, Inc. (KLRS) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Kalaris Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Popular Vehicles and Services Limited
NSE:PVSL
|
-0.018x |
|
Eksun Gida Tarim Sanayi ve Ticaret A.S.
IS:EKSUN
|
0.011x |
|
Greenheart Gold Inc.
V:GHRT
|
-0.089x |
|
Alcidion Group Ltd
AU:ALC
|
0.113x |
|
Delta Djakarta Tbk
JK:DLTA
|
0.097x |
|
Ibkimyoung Co. Ltd
KQ:339950
|
0.107x |
|
SUN KWANG CO.Ltd
KQ:003100
|
0.035x |
|
Taiwan IC Packaging
TWO:3372
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Kalaris Therapeutics, Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see KLRS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.81 Million | $-42.98 Million | -0.545x | +8.74% |
| 2024-12-31 | $113.31 Million | $-67.70 Million | -0.598x | -290.34% |
| 2023-12-31 | $-45.02 Million | $-14.13 Million | 0.314x | -2.82% |
| 2022-12-31 | $-30.27 Million | $-9.78 Million | 0.323x | +168.44% |
| 2021-12-31 | $225.27 Million | $-106.32 Million | -0.472x | -174.02% |
| 2020-12-31 | $353.06 Million | $-60.81 Million | -0.172x | -3.94% |
| 2019-12-31 | $121.62 Million | $-20.16 Million | -0.166x | -284.07% |
| 2018-12-31 | $21.58 Million | $1.94 Million | 0.090x | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more